Research programme: immunotherapeutics - Nextera AS
Latest Information Update: 27 Oct 2015
At a glance
- Originator Nextera
- Mechanism of Action HLA antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Crohn's disease; Haematological malignancies
Most Recent Events
- 21 Sep 2015 Nextera AS and Janssen Biotech agree to conduct verification studies using Nextera's technology in Norway for Rheumatoid Arthritis
- 21 Sep 2015 Early research in Crohn's disease in Norway (unspecified route)
- 21 Sep 2015 Early research in Haematological malignancies in Norway (unspecified route)